nach oben

Journal of General Internal Medicine

Erschienen in:

29.01.2021 | Review Paper

Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review

verfasst von: Premalatha Balachandran, PhD, Mahmoud Elsohly, PhD, Kevin P. Hill, MD, MHS

Erschienen in: Journal of General Internal Medicine | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Cannabidiol, a non-intoxicating phytocannabinoid, has potential therapeutic effects over a broad range of disorders. Recently, there has been increased interest in CBD, as several studies showed promising anticonvulsant efficacy with few side effects. In 2018, a CBD-based oral solution, Epidiolex®, was approved by the FDA to treat two severe forms of pediatric epilepsy, Dravet syndrome, and Lennox-Gastaut syndrome. Although only these two syndromes are recognized indications for CBD, it has been consumed in an unregulated fashion for a variety of indications including chronic pain, muscle stiffness, inflammation, anxiety, smoking cessation, and even cancer. While CBD legislation in the USA is confusing due to the differences in state and federal laws, CBD has proliferated in the US market in several forms such as CBD oil or capsules, hemp oil/extract, and also as an ingredient in several dietary supplements, syrups, teas, and creams. With the ever-increasing use of CBD and its widespread availability to the general public, it is important to examine and report on possible drug–drug interactions between CBD and other therapeutic agents as well as addictive substances such as alcohol and tobacco. A detailed literature search for CBD’s possible interactions was conducted using online databases. As expected, CBD has been reported to interact with anti-epileptic drugs, antidepressants, opioid analgesics, and THC, but surprisingly, it interacts with several other common medications, e.g. acetaminophen, and substances including alcohol. This review provides a comprehensive list of interacting drugs. The possible mechanisms for these drug–drug interactions are presented in table format. Given the growing popularity of CBD as a medication and the dearth of available information on CBD drug–drug interactions, it is critical to be aware of current drug–drug interactions and it will be important to investigate the impact of CBD upon concomitant medication use in future randomized, controlled trials.

ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78(5):539-548.PubMedCrossRef

Joy JE, Watson S, Benson J. Marijuana and Medicine. Assessing the Science Base. 1999:1999.

Mikulic M. Global Pharmaceutical Industry–Statistics & Facts. In: Statista; 2019.

Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791-802.PubMedPubMedCentralCrossRef

Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 2017;175:133-150.PubMedCrossRef

Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 2016;112:119-127.PubMedCrossRef

Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982;83(3-4):293-298.PubMedCrossRef

Coimbra N, Mendes-Gomes J, Da Silva J, Dos Anjos-Garcia T, Ullah F, Almada R. New Ethological and Morphological Perspectives for the Investigation of Panicolytic-Like Effects of Cannabidiol. In: Handbook of Cannabis and Related Pathologies. Elsevier; 2017:e140-e149.

Schiavon AP, Bonato JM, Milani H, Guimarães FS, de Oliveira RMW. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog Neuro-Psychopharmacol Biol Psychiatry 2016;64:27-34.CrossRef

10.

Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011;89(5-6):165-170.PubMedCrossRef

11.

Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metabolism and Pharmacokinetics. 2013:DMPK-12-RG-129.

12.

Zendulka O, Dovrtelová G, Nosková K, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 2016;17(3):206-226.PubMedCrossRef

13.

Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta (9)-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005;70(7):1096-1103.PubMedCrossRef

14.

Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246-1251.PubMedCrossRef

15.

Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, Crippa AS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011;6(4):237-249.CrossRef

16.

Monographie N. Cannabidiol. Deutscher Arzneimittel-Codex (DAC) inkl Neues Rezeptur-Formularium (NRF) DAC/NRF October. 2015;22.

17.

Wedman-St Louis B. 14 Drug Interactions & Dosing Issues. Cannabis as Medicine. 2019.

18.

Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci 2008;105(7):2699-2704.PubMedPubMedCentralCrossRef

19.

Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid-and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci 2013;110(13):5193-5198.PubMedPubMedCentralCrossRef

20.

Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci 2017;114(42):11229-11234.PubMedPubMedCentralCrossRef

21.

Feinshtein V, Erez O, Ben-Zvi Z, et al. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ. 2013;1:e153.PubMedPubMedCentralCrossRef

22.

Database MC. https://reference.medscape.com/drug-interactionchecker Accessed March 28 2020.

23.

Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 2018;19(3):833.PubMedCentralCrossRef

24.

Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2017;2(1):139-154.PubMedPubMedCentralCrossRef

25.

van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860.PubMedCrossRef

26.

Khoury JM, Neves MdCLd, Roque MAV, et al. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry 2019;20(2):101-116.PubMedCrossRef

27.

Database DB. https://www.drugbank.ca/drugs/DB09061/biointeractions#target-tab Accessed April 15 2020.

28.

Chesher G, Jackson DM. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia. 1974;37(3):255-264.PubMedCrossRef

29.

Consroe P, Wolkin A. Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201(1):26-32.PubMed

30.

Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 1980;28(1):115-120.PubMedCrossRef

31.

Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39(11):2049-2056.PubMedCrossRef

32.

Naccarato M, Yoong D, Kovacs C, Gough K. Case report a case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther 2012;17:589-592.PubMedCrossRef

33.

Giraud C, Tran A, Rey E, Vincent J, Tréluyer J-M, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004;32(11):1279-1286.PubMedCrossRef

34.

Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 2012;32(4):340-353.PubMedCrossRef

35.

Morrison G, Crockett J, Blakey G, Sommerville K. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev 2019;8(8):1009-1031.PubMedPubMedCentralCrossRef

36.

Grotenhermen F, Gebhardt K, Berger M. Cannabidiol. Solothurn, Schweiz: Nachtschatten Verlag 2016:17-63.

37.

Gaston TE, Szaflarski JP. Cannabis for the treatment of epilepsy: an update. Curr Neurol Neurosci Rep 2018;18(11):73.PubMedCrossRef

38.

Consroe PF, AL Wolkin Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977;29(8):500-501.PubMed

39.

Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytotherapy Res 2009;23(5):597-602.CrossRef

40.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP, Program UC. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586-1592.PubMedCrossRef

41.

Gaston TE, Bebin EM, Cutter GR, et al. Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. Epilepsy Behav 2019;98:201-206.PubMedCrossRef

42.

Socała K, Wyska E, Szafarz M, Nieoczym D, Wlaź P. Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock-and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. Neuropharmacology. 2019;158:107733.PubMedCrossRef

43.

Ujváry I, Hanuš L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res 2016;1(1):90-101.PubMedPubMedCentralCrossRef

44.

Păunescu H, Coman O, Coman L, et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011;4(1):11.PubMedPubMedCentral

45.

Gasparyan A, Navarrete F, Manzanares J. P. 417 Effects of cannabidiol and sertraline on behavioral and neurochemical alterations induced by a new long-lasting animal model of PTSD. Eur Neuropsychopharmacol. 2019;29:S296.CrossRef

46.

Sales AJ, Crestani CC, Guimarães FS, Joca SR. Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Prog Neuro-Psychopharmacol Biol Psychiatry 2018;86:255-261.CrossRef

47.

Wilson-Morkeh H, Al-Abdulla A, Sien L, Mohamed H, Youngstein T. Important drug interactions exist between cannabidiol oil and commonly prescribed drugs in rheumatology practice. Rheumatology. 2020.

48.

Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA. Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol 2015;26(3):304-314.PubMedCrossRef

49.

Qian Y, Gilliland TK, Markowitz JS. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem Biol Interact 2020;316:108914.PubMedCrossRef

50.

Manini AF, Yiannoulos G, Bergamaschi MM, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med 2015;9(3):204.PubMedPubMedCentralCrossRef

51.

ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. In: Phytocannabinoids. Springer; 2017:1-36.

52.

Zuardi AW, Shirakawa I, Finkelfarb E, Karniol I. Action of cannabidiol on the anxiety and other effects produced by Δ 9-THC in normal subjects. Psychopharmacology. 1982;76(3):245-250.PubMedCrossRef

53.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ 9-tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142-154.PubMedCrossRef

54.

Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764-774.PubMedCrossRef

55.

King KM, Myers AM, Soroka-Monzo AJ, et al. Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol 2017;174(17):2832-2841.PubMedPubMedCentralCrossRef

56.

Todd S, Arnold J. Neural correlates of interactions between cannabidiol and Δ9-tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol 2016;173(1):53-65.PubMedCrossRef

57.

Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Δ 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35(9):1879-1885.PubMedPubMedCentralCrossRef

58.

Todd SM, Zhou C, Clarke DJ, Chohan TW, Bahceci D, Arnold JC. Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. Eur Neuropsychopharmacol 2017;27(2):132-145.PubMedCrossRef

59.

Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018;84(11):2477-2482.PubMedPubMedCentralCrossRef

60.

Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol 2019;124(1):28-31.PubMedCrossRef

61.

Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant 2019;19(10):2944-2948.PubMedCrossRef

62.

Brown JD, Winterstein AG. Potential adverse drug events and drug–drug interactions with medical and consumer Cannabidiol (CBD) use. J Clin Med 2019;8(7):989.PubMedCentralCrossRef

63.

Ewing LE, McGill MR, Yee EU, et al. Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration. Molecules. 2019;24(12):2256.PubMedCentralCrossRef

64.

dos-Santos-Pereira M, da-Silva CA, Guimaraes FS, Del-Bel E. Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol Dis 2016;94:179-195.PubMedCrossRef

65.

Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Transact R Soc B: Biol Sci 2013;368(1612):20120431.CrossRef

66.

Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011;88(15-16):730-736.PubMedCrossRef

67.

Nona CN, Hendershot CS, Le Foll B. Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research. Exp Clin Psychopharmacol 2019;27(4):359.PubMedCrossRef

68.

Yang L, Rozenfeld R, Wu D, Devi LA, Zhang Z, Cederbaum A. Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. Free Radic Biol Med 2014;68:260-267.PubMedPubMedCentralCrossRef

69.

Hamelink C, Hampson A, Wink DA, Eiden LE, Eskay RL. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther 2005;314(2):780-788.PubMedCrossRef

70.

Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993;18(3):247-291.PubMedCrossRef

71.

Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. Psychopharmacology. 1979;66(1):45-50.PubMedCrossRef

Titel: Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review
verfasst von: Premalatha Balachandran, PhD
Mahmoud Elsohly, PhD
Kevin P. Hill, MD, MHS
Publikationsdatum: 29.01.2021
Verlag: Springer International Publishing
Erschienen in: Journal of General Internal Medicine / Ausgabe 7/2021
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-020-06504-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Residents’ Perceptions of Faculty Behaviors and Resident Burnout: a Cross-Sectional Survey Study Across a Large Health Care Organization

Barriers to Accessing Nighttime Supervisors: a National Survey of Internal Medicine Residents

Health Literacy, Processing Capacity, Illness Knowledge, and Actionable Memory for Medication Taking in Type 2 Diabetes: Cross-Sectional Analysis

Comparative Effectiveness of a Complex Care Program for High-Cost/High-Need Patients: a Retrospective Cohort Study

Characterizing the Role of the “Triagist”: Reasons for Triage Discordance and Impact on Disposition

Hospital-Level Care at Home for Acutely Ill Adults: a Qualitative Evaluation of a Randomized Controlled Trial

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Proximale Humerusfraktur: Auch 100-Jährige operieren?

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Update Innere Medizin